floxuridine has been researched along with Local Neoplasm Recurrence in 85 studies
Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We conducted a phase II study to determine the availability and safety of combination chemotherapy with weekly paclitaxel and doxifluridine (a capecitabine metabolite) in the treatment of advanced or recurrent breast cancer." | 9.13 | Efficacy of doxifluridine combined with weekly paclitaxel therapy in the treatment of advanced or recurrent breast cancer: results of the JMTO BC01 phase II trial. ( Asaishi, K; Doi, T; Inaba, M; Kimura, M; Nishimura, R; Okamoto, Y; Okuyama, N; Takeuchi, H; Tamaki, N; Tominaga, T; Yanagita, Y, 2008) |
| "Twenty-four eligible patients (23 of whom were evaluated) with advanced and metastatic breast cancer were treated at the Saitama Cancer Center every 4 weeks with pirarubicin (30 mg/m2 i." | 9.09 | [Therapeutic efficacy of pirarubicin cyclophosphamide and doxifluridine in advanced and metastatic breast cancer]. ( Higashi, Y; Inoue, K; Kurosumi, M; Suemasu, K; Tabei, T, 1999) |
| "We investigated efficacy and tolerance of chemotherapy with doxifluridine (5'-DFUR) and docetaxel (TXT) in advanced/recurrent breast cancer." | 9.09 | [A phase I study of docetaxel (TXT) and doxifluridine (5'-DFUR) combination therapy in patients with advanced and recurrent breast cancer]. ( Aoyama, H; Asaga, T; Iwase, H; Kimura, M; Mitsuyama, S; Nishimura, R; Tominaga, T, 2001) |
| "To evaluate the feasibility and efficacy of weekly paclitaxel and 5'-DFUR combination therapy in advanced or recurrent breast cancer, 13 patients were enrolled in this pilot study." | 7.72 | [Evaluation of weekly paclitaxel and doxifluridine (5'-DFUR) combination therapy in patients with advanced or recurrent breast cancer]. ( Kou, Y; Okamoto, Y; Okuyama, N; Sawada, T; Tominaga, T, 2003) |
| "Two cases of recurrent breast cancer are reported in which chemotherapy with mitoxantrone proved remarkably effective." | 7.70 | [Chemotherapy with mitoxantrone for the treatment of recurrent breast cancer]. ( Katagata, N; Matsuoka, T; Nomizu, T; Takenoshita, S; Tsuchiya, A; Watanabe, F; Yabuta, T; Yamaki, Y, 2000) |
| "A left radical mastectomy was performed on a 53-year-old woman, diagnosed with left inflammatory breast cancer, after local arterial chemotherapy with cyclophosphamide (CPA), doxorubicin and 5-fluorouracil (5-FU)." | 7.70 | [A case of recurrent breast cancer with carcinoma erysipeloides responding to sequential therapy with docetaxel (TXT) and doxifluridine (5'-DFUR) accompanied by leucovorin (LV)]. ( Gen, T; Hara, Y; Igarashi, K; Jibiki, M; Kawasaki, T; Kikuchi, M; Kudoh, A; Noguchi, N; Yabata, E, 2000) |
| "We treated fifteen patients with recurrent breast cancer by a combination of mitoxantrone (8 mg/m i." | 7.69 | [Efficacy of combination chemotherapy with mitoxantrone, vincristine, doxifluridine and prednisolone for recurrence of breast cancer]. ( Katsumata, K; Kawasaki, M; Koyanagi, Y; Kusama, M; Moriwaki, R; Murano, A; Nagakawa, Y; Ogata, T; Shibata, K; Yamamoto, K, 1997) |
| "A comparative study was performed to evaluate the efficacy and safety of 5'-DFUR and tegafur in recurrent breast cancer." | 7.67 | [A comparative study of 5'-DFUR and tegafur in recurrent breast cancer]. ( Abe, O; Ogawa, N; Taguchi, T; Terasawa, T; Tominaga, T; Yoshida, Y, 1985) |
| "A total of 112 patients with pTa or pT1 bladder cancer were eligible for the analysis and were allocated to either an adjuvant group (TURBT+5'-DFUR; n = 47; initial 23 months) or a control group (TURBT alone; n = 65, final 23 months)." | 6.71 | Novel prophylactic effect of doxifluridine in superficial bladder cancer. ( Aoki, A; Baba, Y; Jojima, K; Matsuyama, H; Naito, K; Shimabukuro, T; Suga, A; Suyama, K; Uchiyama, K; Yamamoto, N, 2004) |
| "In treating advanced or recurrent breast cancer, anthracycline-containing chemotherapy is used for palliation and to maintain quality of life." | 6.70 | 5'-deoxy-5-fluorouridine, medroxyprogestrone acetate and mitoxantrone hydrochloride for advanced or recurrent breast cancer. ( Akao, S; Hiraide, H; Ishikawa, H; Maruyama, M; Matsumoto, F; Mochizuki, H; Okamura, H; Sato , K; Tabei, T; Tamakuma, S; Touma, M; Yagi, Y, 2001) |
| "A comparative study of 5'-DFUR 600 mg/day alone (C-arm) or in combination with TAM 30 mg/day (A-arm) or MPA 600 mg/day (B-arm) was carried out." | 6.38 | [A comparative study with 5'-DFUR alone or in combination with tamoxifen (TAM) or medroxyprogesterone acetate (MPA) for advanced or recurrent breast cancer]. ( Aikawa, T; Hirai, T; Kotsuma, Y; Maeura, Y; Miyauchi, K; Takatsuka, Y; Yayoi, E, 1992) |
| "Guidelines recommend etoposide, methotrexate, actinomycin D (EMA)/cyclophosphamide, vincristine (CO) as first-line treatment for high-risk gestational trophoblastic neoplasia (GTN)." | 5.51 | Efficacies of FAEV and EMA/CO regimens as primary treatment for gestational trophoblastic neoplasia. ( Feng, F; Ji, M; Jiang, S; Ren, T; Wan, X; Xiang, Y; Yang, J; Zhao, J, 2022) |
| "Although most patients with gestational trophoblastic neoplasia (GTN) are cured by conventional chemotherapy, some develop drug resistance or relapse." | 5.37 | Salvage combination chemotherapy with floxuridine, dactinomycin, etoposide, and vincristine (FAEV) for patients with relapsed/chemoresistant gestational trophoblastic neoplasia. ( Feng, F; Geng, S; Wan, X; Wang, T; Xiang, Y, 2011) |
| "We report a postmenopausal recurrent breast cancer patient with triple negative disease who presented with right recurrent nerve palsy." | 5.35 | [Doxifluridine, medroxyprogesterone acetate and cyclophosphamide (DMpC) combination therapy is effective against recurrent triple negative breast cancer--a case report]. ( Jinta, E; Sakurai, T; Shimizu, S; Suzuma, T; Umemura, T; Yoshimura, G, 2008) |
| "For metastatic breast cancer patients who have hormone receptor-positive tumors, hormonal therapy aiming at optimal palliation and prolongation of life is the initial treatment of choice." | 5.32 | [Combination therapy with Anastrozole and 5'-DFUR as a treatment for metastatic breast cancer]. ( Fuchimoto, S; Inagaki, M; Miyoshi, K; Nakagawa, T; Ohsaki, T; Ohtsuka, S; Yumura, M, 2004) |
| "Concurrent carboplatin chemotherapy did not significantly improve the long-term survival after inductive carboplatin and floxuridine chemotherapy in locoregionally advanced nasopharyngeal carcinoma." | 5.20 | Ten-year outcomes of a randomised trial for locoregionally advanced nasopharyngeal carcinoma: A single-institution experience from an endemic area. ( Cao, KJ; Guo, L; Guo, X; Hong, MH; Huang, PY; Mai, HQ; Mo, HY; Qian, CN; Wu, PH; Zeng, Q, 2015) |
| "We conducted a phase II study to determine the availability and safety of combination chemotherapy with weekly paclitaxel and doxifluridine (a capecitabine metabolite) in the treatment of advanced or recurrent breast cancer." | 5.13 | Efficacy of doxifluridine combined with weekly paclitaxel therapy in the treatment of advanced or recurrent breast cancer: results of the JMTO BC01 phase II trial. ( Asaishi, K; Doi, T; Inaba, M; Kimura, M; Nishimura, R; Okamoto, Y; Okuyama, N; Takeuchi, H; Tamaki, N; Tominaga, T; Yanagita, Y, 2008) |
| "We investigated efficacy and tolerance of chemotherapy with doxifluridine (5'-DFUR) and docetaxel (TXT) in advanced/recurrent breast cancer." | 5.09 | [A phase I study of docetaxel (TXT) and doxifluridine (5'-DFUR) combination therapy in patients with advanced and recurrent breast cancer]. ( Aoyama, H; Asaga, T; Iwase, H; Kimura, M; Mitsuyama, S; Nishimura, R; Tominaga, T, 2001) |
| "Twenty-four eligible patients (23 of whom were evaluated) with advanced and metastatic breast cancer were treated at the Saitama Cancer Center every 4 weeks with pirarubicin (30 mg/m2 i." | 5.09 | [Therapeutic efficacy of pirarubicin cyclophosphamide and doxifluridine in advanced and metastatic breast cancer]. ( Higashi, Y; Inoue, K; Kurosumi, M; Suemasu, K; Tabei, T, 1999) |
| "Fifty-nine patients with invasive primary gastric adenocarcinoma who were deemed resectable for cure entered a clinical trial that called for 2 cycles of protracted infusion 5-fluorouracil with weekly leucovorin and cisplatin chemotherapy followed by surgery." | 5.08 | Systemic chemotherapy for gastric carcinoma followed by postoperative intraperitoneal therapy: a final report. ( Baranda, J; Casagrande, Y; Crookes, P; Groshen, S; Laine, L; Leichman, CG; Leichman, L; Silberman, H; Stain, S; Tan, M, 1997) |
| "High-dose toremifene therapy (120 mg/day) is useful for the recurrence of receptor-positive breast cancer." | 3.74 | [Evaluation of combination therapy of high-dose toremifene and oral chemotherapy]. ( Murakami, S; Yamamoto, Y, 2007) |
| "To evaluate the feasibility and efficacy of weekly paclitaxel and 5'-DFUR combination therapy in advanced or recurrent breast cancer, 13 patients were enrolled in this pilot study." | 3.72 | [Evaluation of weekly paclitaxel and doxifluridine (5'-DFUR) combination therapy in patients with advanced or recurrent breast cancer]. ( Kou, Y; Okamoto, Y; Okuyama, N; Sawada, T; Tominaga, T, 2003) |
| "Two cases of recurrent breast cancer are reported in which chemotherapy with mitoxantrone proved remarkably effective." | 3.70 | [Chemotherapy with mitoxantrone for the treatment of recurrent breast cancer]. ( Katagata, N; Matsuoka, T; Nomizu, T; Takenoshita, S; Tsuchiya, A; Watanabe, F; Yabuta, T; Yamaki, Y, 2000) |
| "A left radical mastectomy was performed on a 53-year-old woman, diagnosed with left inflammatory breast cancer, after local arterial chemotherapy with cyclophosphamide (CPA), doxorubicin and 5-fluorouracil (5-FU)." | 3.70 | [A case of recurrent breast cancer with carcinoma erysipeloides responding to sequential therapy with docetaxel (TXT) and doxifluridine (5'-DFUR) accompanied by leucovorin (LV)]. ( Gen, T; Hara, Y; Igarashi, K; Jibiki, M; Kawasaki, T; Kikuchi, M; Kudoh, A; Noguchi, N; Yabata, E, 2000) |
| "We treated fifteen patients with recurrent breast cancer by a combination of mitoxantrone (8 mg/m i." | 3.69 | [Efficacy of combination chemotherapy with mitoxantrone, vincristine, doxifluridine and prednisolone for recurrence of breast cancer]. ( Katsumata, K; Kawasaki, M; Koyanagi, Y; Kusama, M; Moriwaki, R; Murano, A; Nagakawa, Y; Ogata, T; Shibata, K; Yamamoto, K, 1997) |
| "A comparative study was performed to evaluate the efficacy and safety of 5'-DFUR and tegafur in recurrent breast cancer." | 3.67 | [A comparative study of 5'-DFUR and tegafur in recurrent breast cancer]. ( Abe, O; Ogawa, N; Taguchi, T; Terasawa, T; Tominaga, T; Yoshida, Y, 1985) |
| " No DLT was observed in level 2, and this combination therapy seemed safe and feasible for outpatients." | 2.72 | [Evaluation of safety and efficacy for bi-weekly Docetaxel and 5'-DFUR combination therapy in patients with advanced or recurrent breast cancer--Phase I study]. ( Ikeda, M; Ishiguro, K; Kataoka, T; Komaki, K; Kurebayashi, J; Morimoto, T; Sonoo, H; Tanaka, K; Tangoku, A; Yoshizawa, K, 2006) |
| "A total of 112 patients with pTa or pT1 bladder cancer were eligible for the analysis and were allocated to either an adjuvant group (TURBT+5'-DFUR; n = 47; initial 23 months) or a control group (TURBT alone; n = 65, final 23 months)." | 2.71 | Novel prophylactic effect of doxifluridine in superficial bladder cancer. ( Aoki, A; Baba, Y; Jojima, K; Matsuyama, H; Naito, K; Shimabukuro, T; Suga, A; Suyama, K; Uchiyama, K; Yamamoto, N, 2004) |
| " The mean dosage per course of TXT was 58." | 2.71 | [Bi-weekly chemotherapy with medium-dose docetaxel for advanced and recurrent breast cancers (The 15th study of Keiji Breast Cancer Study Group)]. ( Fujii, K; Fujino, S; Higashide, S; Hori, T; Inamoto, T; Kan, N; Lee, CJ; Maruhashi, K; Mise, K; Mitsumori, M; Nishimura, S; Okamoto, M; Okamura, T; Sawai, S; Takemoto, Y; Yamauchi, A, 2005) |
| " The purpose of the present study was to examine the efficacy of long-term administration of 5'-DFUR/CPA for patients with recurrent breast cancer." | 2.71 | The efficacy of long-term oral chemotherapy with 5'-deoxy-5-fluorouridine and cyclophosphamide for recurrent breast cancer. ( Aihara, N; Fukunaga, M; Iba, T; Kidokoro, A; Suda, M; Sugiyama, K, 2004) |
| "Most colorectal cancers metastatic to the liver are resistant to chemotherapy and are not amenable to surgical resection." | 2.70 | Systemic irinotecan or regional floxuridine chemotherapy prolongs survival after hepatic cryosurgery in patients with metastatic colon cancer refractory to 5-fluorouracil. ( Bilchik, AJ; Chawla, SP; Chung, MH; Foshag, LJ; Ramming, KP; Rose, DM; Stern, SS; Wood, TF, 2001) |
| "In treating advanced or recurrent breast cancer, anthracycline-containing chemotherapy is used for palliation and to maintain quality of life." | 2.70 | 5'-deoxy-5-fluorouridine, medroxyprogestrone acetate and mitoxantrone hydrochloride for advanced or recurrent breast cancer. ( Akao, S; Hiraide, H; Ishikawa, H; Maruyama, M; Matsumoto, F; Mochizuki, H; Okamura, H; Sato , K; Tabei, T; Tamakuma, S; Touma, M; Yagi, Y, 2001) |
| "Patients with one to three potentially resectable metastases were randomized preoperatively to receive no further therapy (control arm, 56 patients) or postoperative hepatic arterial floxuridine combined with intravenous continuous-infusion fluorouracil (chemotherapy arm, 53 patients)." | 2.70 | Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy--an intergroup study. ( Adak, S; Benson, AB; Gray, B; Kemeny, MM; Lipsitz, S; Macdonald, JS; O'Dwyer, PJ; Sigurdson, ER; Smith, T, 2002) |
| "However, in bladder cancer, response rates have only been reported in Phase II clinical trials." | 2.69 | [5'-DFUR chemoprophylaxis in superficial bladder cancer. Kanagawa Urology 5'-DFUR Study Group]. ( Chiba, K; Ebato, T; Fukuda, M; Fukuoka, H; Fukushima, S; Hirokawa, M; Hosaka, M; Ikeda, I; Kanno, H; Kitami, K; Kondo, I; Kubota, Y; Masuda, M; Miura, T; Miyai, K; Moriyama, M; Noguchi, K; Noguchi, S; Sasaki, K; Sato, K; Senga, Y, 2000) |
| "Leukocytopenia was more severe in group B." | 2.67 | [Sequential methotrexate/5-fluorouracil therapy with 5'-deoxy-5-fluorouridine against advanced gastric cancer: comparison between bolus injection and drip infusion of 5-fluorouracil administration. Hirosaki Cooperative Study Group for Cancer Chemotherapy] ( Ito, T; Komatsu, Y; Moriya, N; Ogasawara, H; Saito, S; Sakata, Y; Sugimoto, N; Tamura, Y; Tsushima, K; Yamada, Y, 1994) |
| " Fluorodeoxyuridine (FUDR) or 5-fluorouracil (5-FU) was used as the agent and a total dosage of 10-20 g was administered for 6-12 months in most studies." | 2.41 | [The role of prophylactic hepatic arterial infusion chemotherapy after potentially curative resection of hepatic metastases from colorectal cancer]. ( Monden, T; Tono, T, 2000) |
| "A comparative study of 5'-DFUR 600 mg/day alone (C-arm) or in combination with TAM 30 mg/day (A-arm) or MPA 600 mg/day (B-arm) was carried out." | 2.38 | [A comparative study with 5'-DFUR alone or in combination with tamoxifen (TAM) or medroxyprogesterone acetate (MPA) for advanced or recurrent breast cancer]. ( Aikawa, T; Hirai, T; Kotsuma, Y; Maeura, Y; Miyauchi, K; Takatsuka, Y; Yayoi, E, 1992) |
| "Sarcopenia was prevalent (48%) and was associated with a worse survival (HR 2." | 1.48 | Implementation and early outcomes for a surgeon-directed hepatic arterial infusion pump program for colorectal liver metastases. ( Abdel-Misih, S; Beal, EW; Bloomston, M; Chafitz, A; Chakedis, J; Davidson, G; Dillhoff, M; Galo, J; Pawlik, TM; Reardon, J; Schmidt, CR; Sun, S, 2018) |
| "Among 62 patients with ovarian cancer enrolled in IP platinum doublet studies in clinical trials (with etoposide (n = 18), with floxuridine (n = 30), and with topotecan (n = 14)), a deleterious BRCA mutation was eventually identified in 10 patients." | 1.40 | Ovarian cancer in BRCA mutation carriers: improved outcome after intraperitoneal (IP) cisplatin. ( Curtin, J; Downey, A; Edwards, S; Kwa, M; Muggia, F; Reich, E; Wallach, R, 2014) |
| "Although most patients with gestational trophoblastic neoplasia (GTN) are cured by conventional chemotherapy, some develop drug resistance or relapse." | 1.37 | Salvage combination chemotherapy with floxuridine, dactinomycin, etoposide, and vincristine (FAEV) for patients with relapsed/chemoresistant gestational trophoblastic neoplasia. ( Feng, F; Geng, S; Wan, X; Wang, T; Xiang, Y, 2011) |
| "We report a postmenopausal recurrent breast cancer patient with triple negative disease who presented with right recurrent nerve palsy." | 1.35 | [Doxifluridine, medroxyprogesterone acetate and cyclophosphamide (DMpC) combination therapy is effective against recurrent triple negative breast cancer--a case report]. ( Jinta, E; Sakurai, T; Shimizu, S; Suzuma, T; Umemura, T; Yoshimura, G, 2008) |
| "Many patients with gastric cancer respond to TS-1, but some fail to respond or have recurrence." | 1.34 | Doxifluridine combined with weekly paclitaxel for second-line treatment in patients with gastric cancer resistant to TS-1. ( Arai, W; Haruta, H; Hirashima, Y; Hosoya, Y; Hyodo, M; Kurashina, K; Nagai, H; Saito, S; Sakuma, K; Yasuda, Y; Yokoyama, T; Zuiki, T, 2007) |
| "We designed a new regimen to evaluate the efficacy and feasibility of weekly paclitaxel combined with orally administered 5'-DFUR therapy against advanced and recurrent gastric cancer." | 1.33 | [Experience of weekly paclitaxel combined with orally administered doxifluridine therapy for advanced and recurrent gastric cancer-preliminary study]. ( Deguchi, Y; Kamimura, K; Kaneko, I; Kii, E; Murata, T; Tsubono, M; Yasumizu, R, 2005) |
| "The data on 307 patients with colorectal cancer at stage II or III, who underwent potentially curative resection with lymphadenectomy, were reviewed." | 1.33 | The MMP-9 expression determined the efficacy of postoperative adjuvant chemotherapy using oral fluoropyrimidines in stage II or III colorectal cancer. ( Ikeda, S; Ishibashi, N; Matono, K; Mizobe, T; Ogata, Y; Ogo, S; Ohkita, A; Ozasa, H; Sasatomi, T; Shirouzu, K, 2006) |
| "For metastatic breast cancer patients who have hormone receptor-positive tumors, hormonal therapy aiming at optimal palliation and prolongation of life is the initial treatment of choice." | 1.32 | [Combination therapy with Anastrozole and 5'-DFUR as a treatment for metastatic breast cancer]. ( Fuchimoto, S; Inagaki, M; Miyoshi, K; Nakagawa, T; Ohsaki, T; Ohtsuka, S; Yumura, M, 2004) |
| "In the field of gastric cancer treatment, especially for patients showing multiple resistance to anticancer drugs, an effective therapy is critically needed." | 1.31 | Effectiveness of doxifluridine (5'-DFUR)/docetaxel against advanced/recurrent gastric cancer showing resistance to various anticancer drug regimens. ( Kurihara, M; Matsukawa, M; Nakamachi, M; Sato, A; Shimada, K; Ushio, J; Yamamoto, W, 2002) |
| "A 55-year-old woman with recurrent breast cancer treated with sequential mastectomies, chemo-and hormonal therapy of UFT, CPM and TAM, achieved remission." | 1.29 | [A case of recurrent breast cancer responding to long-term treatment with 5'-DFUR combined with MPA]. ( Kimura, M; Koida, T; Sekihara, M, 1996) |
| "The authors report a case with esophageal cancer who had undergone a non-curative resection and showed a recurrence." | 1.28 | [A case of recurrent esophageal cancer maintaining complete long-term response after 5'-DFUR and ftorafur administrations]. ( Fujimura, N; Ishida, C; Koyama, S; Maezato, K; Makino, N; Matsukawa, Y; Matsumoto, K; Mizuno, Y; Naitoh, M; Yamamoto, E, 1992) |
| " These dose-response data indicate that locally recurrent tumors are frequently, but not always, different from the original primary tumor in response to chemotherapy agents and ionizing X-irradiation." | 1.27 | Development and characterization of a rat model for locally recurring mammary tumors: sensitivities to 5-fluoro-2'-deoxyuridine, adriamycin, and X-irradiation. ( Aeed, PA; Estrada, J; Welch, DR, 1988) |
| "5'-DFUR was administered orally to recurrent breast cancer patients at a daily dosage of 1,200 mg given 3 times a day for more than 8 weeks." | 1.27 | [Clinical trial of 5'-DFUR in patients with recurrent breast cancer]. ( Komaki, K; Konishi, Y; Miki, H; Monden, Y; Morimoto, T; Ooshimo, K; Tanaka, T; Uomine, Y; Yamakawa, T, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (9.41) | 18.7374 |
| 1990's | 23 (27.06) | 18.2507 |
| 2000's | 38 (44.71) | 29.6817 |
| 2010's | 15 (17.65) | 24.3611 |
| 2020's | 1 (1.18) | 2.80 |
| Authors | Studies |
|---|---|
| Ji, M | 1 |
| Jiang, S | 1 |
| Zhao, J | 1 |
| Wan, X | 2 |
| Feng, F | 2 |
| Ren, T | 1 |
| Yang, J | 1 |
| Xiang, Y | 2 |
| Dhir, M | 1 |
| Zenati, MS | 1 |
| Jones, HL | 1 |
| Bartlett, DL | 1 |
| Choudry, MHA | 1 |
| Pingpank, JF | 1 |
| Holtzman, MP | 1 |
| Bahary, N | 1 |
| Hogg, ME | 1 |
| Zeh, HJ | 1 |
| Geller, DA | 1 |
| Wallis Marsh, J | 1 |
| Tsung, A | 1 |
| Zureikat, AH | 1 |
| Chakedis, J | 1 |
| Beal, EW | 1 |
| Sun, S | 1 |
| Galo, J | 1 |
| Chafitz, A | 1 |
| Davidson, G | 1 |
| Reardon, J | 1 |
| Dillhoff, M | 1 |
| Pawlik, TM | 1 |
| Abdel-Misih, S | 1 |
| Bloomston, M | 1 |
| Schmidt, CR | 1 |
| Buisman, FE | 1 |
| Homs, MYV | 1 |
| Grünhagen, DJ | 1 |
| Filipe, WF | 1 |
| Bennink, RJ | 1 |
| Besselink, MGH | 1 |
| Borel Rinkes, IHM | 1 |
| Bruijnen, RCG | 1 |
| Cercek, A | 1 |
| D'Angelica, MI | 1 |
| van Delden, OM | 1 |
| Donswijk, ML | 1 |
| van Doorn, L | 1 |
| Doornebosch, PG | 1 |
| Emmering, J | 1 |
| Erdmann, JI | 1 |
| IJzerman, NS | 1 |
| Grootscholten, C | 1 |
| Hagendoorn, J | 1 |
| Kemeny, NE | 2 |
| Kingham, TP | 1 |
| Klompenhouwer, EG | 1 |
| Kok, NFM | 1 |
| Koolen, S | 1 |
| Kuhlmann, KFD | 1 |
| Kuiper, MC | 1 |
| Lam, MGE | 1 |
| Mathijssen, RHJ | 1 |
| Moelker, A | 1 |
| Oomen-de Hoop, E | 1 |
| Punt, CJA | 1 |
| Te Riele, WW | 1 |
| Roodhart, JML | 1 |
| Swijnenburg, RJ | 1 |
| Prevoo, W | 1 |
| Tanis, PJ | 1 |
| Vermaas, M | 1 |
| Versleijen, MWJ | 1 |
| Veuger, FP | 1 |
| Weterman, MJ | 1 |
| Verhoef, C | 1 |
| Groot Koerkamp, B | 1 |
| Kang, YK | 2 |
| Chang, HM | 2 |
| Yook, JH | 2 |
| Ryu, MH | 2 |
| Park, I | 1 |
| Min, YJ | 1 |
| Zang, DY | 2 |
| Kim, GY | 1 |
| Yang, DH | 2 |
| Jang, SJ | 2 |
| Park, YS | 2 |
| Lee, JL | 2 |
| Kim, TW | 2 |
| Oh, ST | 1 |
| Park, BK | 1 |
| Jung, HY | 2 |
| Kim, BS | 2 |
| Yoshino, S | 1 |
| Furuya, T | 1 |
| Shimizu, R | 1 |
| Ozasa, H | 3 |
| Nishimura, T | 1 |
| Fukuda, S | 1 |
| Kawaoka, T | 1 |
| Hazama, S | 1 |
| Oka, M | 1 |
| Kwa, M | 1 |
| Edwards, S | 1 |
| Downey, A | 1 |
| Reich, E | 1 |
| Wallach, R | 1 |
| Curtin, J | 1 |
| Muggia, F | 2 |
| Yoo, C | 1 |
| Lee, YJ | 1 |
| Kim, JH | 1 |
| Huang, PY | 1 |
| Zeng, Q | 1 |
| Cao, KJ | 1 |
| Guo, X | 1 |
| Guo, L | 1 |
| Mo, HY | 1 |
| Wu, PH | 1 |
| Qian, CN | 1 |
| Mai, HQ | 1 |
| Hong, MH | 1 |
| Nishimura, R | 2 |
| Tominaga, T | 5 |
| Kimura, M | 4 |
| Yanagita, Y | 1 |
| Tamaki, N | 1 |
| Asaishi, K | 1 |
| Okamoto, Y | 2 |
| Okuyama, N | 2 |
| Takeuchi, H | 1 |
| Inaba, M | 1 |
| Doi, T | 1 |
| Sakurai, T | 2 |
| Umemura, T | 1 |
| Jinta, E | 1 |
| Suzuma, T | 1 |
| Yoshimura, G | 1 |
| Shimizu, S | 1 |
| Huh, JW | 1 |
| Kim, HR | 1 |
| Yoshikawa, T | 1 |
| Tsuburaya, A | 1 |
| Shimada, K | 2 |
| Sato, A | 2 |
| Takahashi, M | 2 |
| Koizumi, W | 1 |
| Yoshizawa, Y | 1 |
| Nabeshima, K | 1 |
| Hataya, K | 1 |
| Kobayashi, O | 1 |
| Samaras, P | 1 |
| Breitenstein, S | 1 |
| Haile, SR | 1 |
| Stenner-Liewen, F | 1 |
| Heinrich, S | 1 |
| Feilchenfeldt, J | 1 |
| Renner, C | 1 |
| Knuth, A | 1 |
| Pestalozzi, BC | 1 |
| Clavien, PA | 1 |
| Geng, S | 1 |
| Wang, T | 1 |
| Takeyoshi, I | 1 |
| Makita, F | 1 |
| Tanahashi, Y | 1 |
| Iwazaki, S | 1 |
| Ogawa, T | 1 |
| Tomizawa, N | 1 |
| Nakamura, S | 1 |
| Ishikawa, H | 2 |
| Ohya, T | 1 |
| Kakinuma, S | 1 |
| Nakagami, K | 1 |
| Sato, Y | 1 |
| Koyano, T | 1 |
| Roppongi, T | 1 |
| Izumi, M | 1 |
| Kobayashi, J | 1 |
| Kawate, S | 1 |
| Sunose, Y | 1 |
| Kobayashi, M | 1 |
| Yamada, T | 2 |
| Sakamoto, I | 1 |
| Bolton, JS | 1 |
| O'Connell, MJ | 1 |
| Mahoney, MR | 1 |
| Farr, GH | 1 |
| Fitch, TR | 1 |
| Maples, WJ | 1 |
| Nagorney, DM | 1 |
| Rubin, J | 1 |
| Fuloria, J | 1 |
| Steen, PD | 1 |
| Alberts, SR | 1 |
| Cohen, DJ | 1 |
| Newman, E | 1 |
| Iqbal, S | 1 |
| Chang, RY | 1 |
| Potmesil, M | 1 |
| Ryan, T | 1 |
| Donahue, B | 1 |
| Chandra, A | 1 |
| Liu, M | 1 |
| Utate, M | 1 |
| Hiotis, S | 1 |
| Pachter, LH | 1 |
| Hochster, H | 1 |
| Yakabe, T | 1 |
| Noshiro, H | 1 |
| Ikeda, O | 1 |
| Miyoshi, A | 1 |
| Kitajima, Y | 1 |
| Satoh, S | 1 |
| Wagner, PL | 1 |
| Jones, D | 1 |
| Aronova, A | 1 |
| Shia, J | 1 |
| Weiser, MR | 1 |
| Temple, LK | 1 |
| Chung, KY | 1 |
| O'Reilly, EM | 1 |
| Kelsen, D | 1 |
| Paty, PB | 1 |
| Nash, GM | 1 |
| Bilchik, AJ | 2 |
| Wood, TF | 1 |
| Chawla, SP | 1 |
| Rose, DM | 1 |
| Chung, MH | 1 |
| Stern, SS | 1 |
| Foshag, LJ | 1 |
| Ramming, KP | 1 |
| Nakamachi, M | 1 |
| Ushio, J | 1 |
| Yamamoto, W | 1 |
| Kurihara, M | 1 |
| Matsukawa, M | 1 |
| Sawada, T | 1 |
| Kou, Y | 1 |
| Wang, H | 1 |
| Li, H | 1 |
| Zang, M | 1 |
| Xu, F | 1 |
| Kato, T | 1 |
| Kikkawa, N | 2 |
| Tsujie, M | 1 |
| Iijima, S | 1 |
| Handa, R | 1 |
| Naoi, Y | 1 |
| Oshima, S | 1 |
| Yamamoto, H | 2 |
| Kurokawa, E | 1 |
| Suzuki, O | 1 |
| Sekishita, Y | 1 |
| Shiono, T | 1 |
| Kondo, S | 1 |
| Kato, H | 1 |
| Miyoshi, K | 1 |
| Ohtsuka, S | 1 |
| Inagaki, M | 1 |
| Ohsaki, T | 1 |
| Fuchimoto, S | 1 |
| Yumura, M | 1 |
| Nakagawa, T | 1 |
| Iba, T | 1 |
| Kidokoro, A | 1 |
| Fukunaga, M | 1 |
| Sugiyama, K | 1 |
| Aihara, N | 1 |
| Suda, M | 1 |
| Yoshitani, S | 1 |
| Imaizumi, H | 1 |
| Kuroda, M | 1 |
| Yokoi, M | 1 |
| Tanaka, Y | 1 |
| Harada, H | 1 |
| Kosaka, T | 1 |
| Takashima, S | 2 |
| Matsuyama, H | 1 |
| Baba, Y | 1 |
| Shimabukuro, T | 1 |
| Uchiyama, K | 1 |
| Aoki, A | 1 |
| Suga, A | 1 |
| Jojima, K | 1 |
| Suyama, K | 1 |
| Yamamoto, N | 1 |
| Naito, K | 1 |
| Fujino, S | 1 |
| Kan, N | 1 |
| Lee, CJ | 1 |
| Inamoto, T | 1 |
| Mise, K | 1 |
| Sawai, S | 1 |
| Okamoto, M | 1 |
| Nishimura, S | 1 |
| Hori, T | 1 |
| Maruhashi, K | 1 |
| Yamauchi, A | 1 |
| Fujii, K | 1 |
| Mitsumori, M | 1 |
| Higashide, S | 1 |
| Takemoto, Y | 1 |
| Okamura, T | 1 |
| Ogata, Y | 2 |
| Matono, K | 2 |
| Sasatomi, T | 1 |
| Ishibashi, N | 2 |
| Ohkita, A | 1 |
| Mizobe, T | 2 |
| Ogo, S | 1 |
| Ikeda, S | 2 |
| Shirouzu, K | 2 |
| Tsubono, M | 1 |
| Kaneko, I | 1 |
| Kii, E | 1 |
| Murata, T | 1 |
| Kamimura, K | 1 |
| Deguchi, Y | 1 |
| Yasumizu, R | 1 |
| Tanaka, K | 2 |
| Noura, S | 1 |
| Ohue, M | 1 |
| Takachi, K | 1 |
| Kishi, K | 1 |
| Eguchi, H | 1 |
| Miyashiro, I | 1 |
| Yano, M | 1 |
| Ohigashi, H | 2 |
| Sasaki, Y | 2 |
| Ishikawa, O | 2 |
| Imaoka, S | 3 |
| Kameyama, M | 2 |
| Murata, K | 1 |
| Mizutani, S | 1 |
| Oyama, T | 1 |
| Hatanaka, N | 1 |
| Uchikoshi, F | 1 |
| Yoshidome, K | 1 |
| Tori, M | 1 |
| Ueshima, S | 1 |
| Okuma, K | 1 |
| Hiraoka, K | 1 |
| Yamagami, Y | 1 |
| Takahashi, H | 1 |
| Sueyoshi, K | 1 |
| Taira, M | 1 |
| Nakahara, M | 1 |
| Nakao, K | 1 |
| Mori, S | 1 |
| Akagi, Y | 1 |
| Murakami, H | 1 |
| Ikeda, M | 1 |
| Sonoo, H | 2 |
| Kurebayashi, J | 1 |
| Morimoto, T | 3 |
| Tangoku, A | 1 |
| Komaki, K | 2 |
| Kataoka, T | 1 |
| Ishiguro, K | 1 |
| Yoshizawa, K | 1 |
| Gotoh, J | 1 |
| Akabane, H | 1 |
| Kita, K | 1 |
| Fujiyoshi, M | 1 |
| Hirokata, G | 1 |
| Imai, K | 1 |
| Kawai, T | 1 |
| Yanagida, N | 1 |
| Nakano, S | 1 |
| Arai, W | 1 |
| Hosoya, Y | 1 |
| Hyodo, M | 1 |
| Haruta, H | 1 |
| Kurashina, K | 1 |
| Saito, S | 2 |
| Hirashima, Y | 1 |
| Yokoyama, T | 1 |
| Zuiki, T | 1 |
| Sakuma, K | 1 |
| Yasuda, Y | 1 |
| Nagai, H | 1 |
| Murakami, S | 1 |
| Yamamoto, Y | 1 |
| Takiuchi, H | 1 |
| Goto, M | 1 |
| Imamura, H | 1 |
| Furukawa, H | 1 |
| Imano, M | 1 |
| Imamoto, H | 1 |
| Kimura, Y | 1 |
| Ishida, H | 1 |
| Fujitani, K | 1 |
| Narahara, H | 1 |
| Shimokawa, T | 1 |
| Nakata, E | 1 |
| Okajima, K | 1 |
| Ishida, Y | 1 |
| Munetomo, Y | 1 |
| Gotoh, K | 1 |
| Toyohara, M | 1 |
| Miyazaki, H | 1 |
| Matsunaga, S | 1 |
| Maeura, Y | 2 |
| Fujimura, T | 1 |
| Kelsen, DP | 1 |
| Saltz, L | 1 |
| Cohen, AM | 1 |
| Yao, TJ | 1 |
| Enker, W | 1 |
| Tong, W | 1 |
| Tao, Y | 1 |
| Bertino, JR | 1 |
| Takahashi, K | 1 |
| Mori, T | 1 |
| Takahashi, T | 1 |
| Nakamori, S | 1 |
| Yasuda, T | 1 |
| Nakano, H | 1 |
| Hiratsuka, M | 1 |
| Kabuto, T | 1 |
| Yamada, Y | 1 |
| Tsushima, K | 2 |
| Sakata, Y | 2 |
| Ito, T | 1 |
| Sugimoto, N | 1 |
| Ogasawara, H | 2 |
| Tamura, Y | 2 |
| Moriya, N | 1 |
| Komatsu, Y | 1 |
| Taguchi, T | 2 |
| Sakai, K | 1 |
| Irie, K | 1 |
| Terasawa, T | 2 |
| Shimoyama, T | 1 |
| Iwanaga, T | 2 |
| Fukuda, I | 1 |
| Okumura, S | 1 |
| Yasutake, K | 3 |
| Enomoto, K | 1 |
| Abe, R | 1 |
| Iino, Y | 1 |
| Koyama, H | 2 |
| Nomura, Y | 1 |
| Abe, O | 2 |
| Nakazato, H | 2 |
| Nishisaki, H | 1 |
| Oya, M | 2 |
| Nakashima, T | 1 |
| Hasegawa, H | 1 |
| Horita, K | 1 |
| Yoshida, R | 1 |
| Nakanishi, Y | 1 |
| Abo, K | 1 |
| Koida, T | 1 |
| Sekihara, M | 1 |
| Crookes, P | 1 |
| Leichman, CG | 1 |
| Leichman, L | 1 |
| Tan, M | 1 |
| Laine, L | 1 |
| Stain, S | 1 |
| Baranda, J | 1 |
| Casagrande, Y | 1 |
| Groshen, S | 2 |
| Silberman, H | 1 |
| Muggia, FM | 1 |
| Jeffers, S | 1 |
| Muderspach, L | 1 |
| Roman, L | 1 |
| Rosales, R | 1 |
| Safra, T | 1 |
| Morrow, CP | 1 |
| Katsumata, K | 1 |
| Yamamoto, K | 1 |
| Shibata, K | 1 |
| Murano, A | 1 |
| Kawasaki, M | 1 |
| Moriwaki, R | 1 |
| Nagakawa, Y | 1 |
| Ogata, T | 1 |
| Koyanagi, Y | 1 |
| Kusama, M | 1 |
| Takatsuka, Y | 2 |
| Shin, E | 1 |
| Davies, MM | 1 |
| Fordy, C | 1 |
| Burke, D | 1 |
| Allen-Mersh, TG | 1 |
| González Barón, M | 1 |
| Inoue, K | 1 |
| Tabei, T | 2 |
| Suemasu, K | 1 |
| Higashi, Y | 1 |
| Kurosumi, M | 1 |
| Senoo, T | 1 |
| Nishiki, M | 1 |
| Tashiro, H | 1 |
| Takahashi, I | 1 |
| Yamamura, S | 1 |
| Ishikawa, T | 1 |
| Yanaga, K | 1 |
| Wakasugi, K | 1 |
| Matsusaka, T | 1 |
| Kume, K | 1 |
| Kokufu, I | 1 |
| Taniguchi, H | 1 |
| Kim, YH | 1 |
| Fukuda, K | 1 |
| Yamamoto, M | 1 |
| Yano, T | 1 |
| Yamada, K | 1 |
| Kitano, H | 1 |
| Takiguchi, N | 1 |
| Nakajima, N | 1 |
| Saitoh, N | 1 |
| Fujimoto, S | 1 |
| Hara, Y | 1 |
| Kawasaki, T | 1 |
| Yabata, E | 1 |
| Gen, T | 1 |
| Jibiki, M | 1 |
| Kudoh, A | 1 |
| Noguchi, N | 1 |
| Igarashi, K | 1 |
| Kikuchi, M | 1 |
| Matsuoka, T | 1 |
| Nomizu, T | 1 |
| Yabuta, T | 1 |
| Katagata, N | 1 |
| Watanabe, F | 1 |
| Yamaki, Y | 1 |
| Tsuchiya, A | 1 |
| Takenoshita, S | 1 |
| Tono, T | 1 |
| Monden, T | 1 |
| Kubota, Y | 1 |
| Noguchi, S | 2 |
| Masuda, M | 1 |
| Hosaka, M | 1 |
| Noguchi, K | 1 |
| Sasaki, K | 1 |
| Miura, T | 1 |
| Ikeda, I | 1 |
| Kondo, I | 1 |
| Senga, Y | 1 |
| Moriyama, M | 1 |
| Fukushima, S | 1 |
| Ebato, T | 1 |
| Fukuda, M | 1 |
| Kitami, K | 1 |
| Fukuoka, H | 1 |
| Sato, K | 1 |
| Hirokawa, M | 1 |
| Chiba, K | 1 |
| Kanno, H | 1 |
| Miyai, K | 1 |
| Iwata, H | 1 |
| Mizutani, M | 1 |
| Iwase, T | 1 |
| Murai, H | 1 |
| Miura, S | 1 |
| Min, JS | 1 |
| Kim, NK | 1 |
| Park, JK | 1 |
| Yun, SH | 1 |
| Noh, JK | 1 |
| Sato , K | 1 |
| Hiraide, H | 1 |
| Tamakuma, S | 1 |
| Maruyama, M | 1 |
| Touma, M | 1 |
| Okamura, H | 1 |
| Matsumoto, F | 1 |
| Akao, S | 1 |
| Yagi, Y | 1 |
| Mochizuki, H | 1 |
| Aoyama, H | 1 |
| Iwase, H | 1 |
| Mitsuyama, S | 1 |
| Asaga, T | 1 |
| Kemeny, MM | 1 |
| Adak, S | 1 |
| Gray, B | 1 |
| Macdonald, JS | 1 |
| Smith, T | 1 |
| Lipsitz, S | 1 |
| Sigurdson, ER | 1 |
| O'Dwyer, PJ | 1 |
| Benson, AB | 1 |
| Miyamoto, H | 1 |
| Yoshida, S | 1 |
| Imatomi, M | 1 |
| Saitoh, T | 1 |
| Nakata, A | 1 |
| Dizon, DS | 1 |
| Mizuno, Y | 1 |
| Makino, N | 1 |
| Matsumoto, K | 1 |
| Fujimura, N | 1 |
| Yamamoto, E | 1 |
| Ishida, C | 1 |
| Koyama, S | 1 |
| Naitoh, M | 1 |
| Maezato, K | 1 |
| Matsukawa, Y | 1 |
| Yayoi, E | 1 |
| Miyauchi, K | 2 |
| Aikawa, T | 1 |
| Hirai, T | 1 |
| Kotsuma, Y | 1 |
| Imamura, Y | 1 |
| Yoshimura, Y | 1 |
| Matsushita, K | 1 |
| Tokisue, M | 1 |
| Ohno, S | 1 |
| Masuda, T | 1 |
| Nishizawa, Y | 1 |
| Inaji, H | 1 |
| Itoh, T | 1 |
| Furukohri, N | 1 |
| Saitoh, S | 1 |
| Baba, T | 1 |
| Munakata, A | 1 |
| Yoshida, Y | 2 |
| Ogawa, N | 1 |
| Hoshino, A | 1 |
| Ohara, K | 1 |
| Kamiya, O | 1 |
| Nagata, K | 1 |
| Ono, Y | 1 |
| Kawakubo, A | 1 |
| Ozaki, Y | 1 |
| Suzuki, A | 1 |
| Ogasawara, T | 1 |
| Sugiura, I | 1 |
| Sears, HF | 1 |
| Shen, JW | 1 |
| Herlyn, M | 1 |
| Atkinson, B | 1 |
| Engstrom, PF | 1 |
| Koprowski, H | 1 |
| Goodman, HM | 1 |
| Dottino, PR | 1 |
| Kredenster, D | 1 |
| Mark, M | 1 |
| Runowicz, C | 1 |
| Cohen, CJ | 1 |
| Welch, DR | 1 |
| Aeed, PA | 1 |
| Estrada, J | 1 |
| Yamakawa, T | 1 |
| Tanaka, T | 1 |
| Konishi, Y | 1 |
| Uomine, Y | 1 |
| Miki, H | 1 |
| Ooshimo, K | 1 |
| Monden, Y | 1 |
| Taylor, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Trial of Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer With Positive Peritoneal Cytology[NCT03092518] | Phase 2 | 27 participants (Actual) | Interventional | 2017-06-05 | Active, not recruiting | ||
| A Multicenter and Prospective Clinical Trial of Gemcitabine-based Induction Chemotherapy Combined With Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma[NCT04522050] | Phase 1 | 65 participants (Anticipated) | Interventional | 2018-10-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for floxuridine and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Arterial chemotherapy as adjuvant and palliative treatment of hepatic colorectal metastases: an update.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy; Flox | 2003 |
[Treatment strategy for recurrent breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cyclophospha | 1998 |
[Oral fluoropyrimidines in oncology].
Topics: Administration, Oral; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplas | 1998 |
[The role of prophylactic hepatic arterial infusion chemotherapy after potentially curative resection of hepatic metastases from colorectal cancer].
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Floxuridine; Fluorouracil; Hepatectomy; Hepat | 2000 |
Intrahepatic arterial infusion of chemotherapy: clinical results.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Floxuridine; Fluor | 2002 |
[A comparative study with 5'-DFUR alone or in combination with tamoxifen (TAM) or medroxyprogesterone acetate (MPA) for advanced or recurrent breast cancer].
Topics: Adult; Aged; Breast Neoplasms; Drug Administration Schedule; Drug Therapy, Combination; Female; Flox | 1992 |
Adjuvant cytotoxic chemotherapy for colorectal cancer: the present position.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combine | 1988 |
36 trials available for floxuridine and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Efficacies of FAEV and EMA/CO regimens as primary treatment for gestational trophoblastic neoplasia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dactinomycin; Etoposide; Female; Floxuridine; Gestat | 2022 |
Adjuvant hepatic arterial infusion pump chemotherapy and resection versus resection alone in patients with low-risk resectable colorectal liver metastases - the multicenter randomized controlled PUMP trial.
Topics: Adult; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; | 2019 |
Adjuvant chemotherapy for gastric cancer: a randomised phase 3 trial of mitomycin-C plus either short-term doxifluridine or long-term doxifluridine plus cisplatin after curative D2 gastrectomy (AMC0201).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Floxurid | 2013 |
Combination phase II study of weekly paclitaxel and 5'-DFUR for unresectable or recurrent gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; | 2013 |
Enhanced efficacy of postoperative adjuvant chemotherapy in advanced gastric cancer: results from a phase 3 randomized trial (AMC0101).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Fema | 2014 |
Ten-year outcomes of a randomised trial for locoregionally advanced nasopharyngeal carcinoma: A single-institution experience from an endemic area.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemoradiotherapy, Ad | 2015 |
Efficacy of doxifluridine combined with weekly paclitaxel therapy in the treatment of advanced or recurrent breast cancer: results of the JMTO BC01 phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival | 2008 |
A phase II study of doxifluridine and docetaxel combination chemotherapy for advanced or recurrent gastric cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Surv | 2009 |
A phase II study of weekly paclitaxel and doxifluridine combination chemotherapy for advanced/recurrent gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cell Differentiation | 2011 |
Hepatic arterial infusion and systemic chemotherapy after multiple metastasectomy in patients with colorectal carcinoma metastatic to the liver: a North Central Cancer Treatment Group (NCCTG) phase II study, 92-46-52.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 2012 |
Systemic irinotecan or regional floxuridine chemotherapy prolongs survival after hepatic cryosurgery in patients with metastatic colon cancer refractory to 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; Camptothecin; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regiona | 2001 |
[Prevention and treatment of bladder tumors recurrence with furtulon].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2000 |
The efficacy of long-term oral chemotherapy with 5'-deoxy-5-fluorouridine and cyclophosphamide for recurrent breast cancer.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast | 2004 |
Novel prophylactic effect of doxifluridine in superficial bladder cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Carcinoma, Transitional Cell; Cystectomy; Dose | 2004 |
[Bi-weekly chemotherapy with medium-dose docetaxel for advanced and recurrent breast cancers (The 15th study of Keiji Breast Cancer Study Group)].
Topics: Adult; Aged; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Bone Marr | 2005 |
[Evaluation of safety and efficacy for bi-weekly Docetaxel and 5'-DFUR combination therapy in patients with advanced or recurrent breast cancer--Phase I study].
Topics: Administration, Oral; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Bone Ne | 2006 |
Multi-center phase II study for combination therapy with paclitaxel/doxifluridine to treat advanced/recurrent gastric cancer showing resistance to S-1 (OGSG 0302).
Topics: Adenocarcinoma; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Disease-Free | 2008 |
[Combination therapy of high dose 5'-DFUR+MMC for advanced or recurrent gastric cancer. 5'-DFUR Joint Research Group in the Osaka District for Gastric Cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Administration Schedule; | 1995 |
A phase I trial of immediate postoperative intraperitoneal floxuridine and leucovorin plus systemic 5-fluorouracil and levamisole after resection of high risk colon cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Th | 1994 |
[Hepatic arterial infusion after hepatectomy for liver metastases of colorectal carcinoma to prevent residual hepatic recurrence].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Floxuridine; Flu | 1994 |
[Adjuvant chemo-endocrine chemotherapy with gastrin antagonist after resection of liver metastasis in colorectal cancer].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj | 1994 |
[Sequential methotrexate/5-fluorouracil therapy with 5'-deoxy-5-fluorouridine against advanced gastric cancer: comparison between bolus injection and drip infusion of 5-fluorouracil administration. Hirosaki Cooperative Study Group for Cancer Chemotherapy]
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Anorexia; Antineoplastic Combined Ch | 1994 |
[A randomized controlled study of maintenance therapy with (2"R)-4'-O-tetrahydropyranyladriamycin for advanced and recurrent breast cancer. Clinical Study Group of THP for Breast Cancer in Japan].
Topics: Adult; Alopecia; Anorexia; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protoco | 1996 |
Systemic chemotherapy for gastric carcinoma followed by postoperative intraperitoneal therapy: a final report.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 1997 |
Phase I/II study of intraperitoneal floxuridine and platinums (cisplatin and/or carboplatin).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carbop | 1997 |
[Therapeutic efficacy of pirarubicin cyclophosphamide and doxifluridine in advanced and metastatic breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dox | 1999 |
[Usefulness of low dose 5'-DFUR (5'-deoxy-5-fluorouridine) for advanced or recurrent breast cancer].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Drug Adm | 1999 |
[Effects of DAC (doxifluridine, adriamycin, cyclophosphamide) chemotherapy in advanced breast cancer patients].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclop | 1999 |
A phase III randomized study comparing oral doxifluridine and oral 5-fluorouracil after curative resection of gastric cancer.
Topics: Administration, Oral; Adult; Aged; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Floxuridin | 2000 |
[5'-DFUR chemoprophylaxis in superficial bladder cancer. Kanagawa Urology 5'-DFUR Study Group].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Female; Flo | 2000 |
A prospective randomized trial comparing intravenous 5-fluorouracil and oral doxifluridine as postoperative adjuvant treatment for advanced rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disea | 2000 |
5'-deoxy-5-fluorouridine, medroxyprogestrone acetate and mitoxantrone hydrochloride for advanced or recurrent breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 2001 |
[A phase I study of docetaxel (TXT) and doxifluridine (5'-DFUR) combination therapy in patients with advanced and recurrent breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Admin | 2001 |
Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy--an intergroup study.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasm | 2002 |
[Clinical trial of a new fluorinated pyrimidine, 5'-deoxy-5-fluorouridine (5'-DFUR)].
Topics: Adult; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Drug Admin | 1986 |
Continuous infusion fluoropyrimidines as salvage therapy for patients with advanced ovarian carcinoma.
Topics: Adult; Aged; Cyclophosphamide; Female; Floxuridine; Fluorouracil; Humans; Infusions, Intravenous; Mi | 1988 |
42 other studies available for floxuridine and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Effectiveness of Hepatic Artery Infusion (HAI) Versus Selective Internal Radiation Therapy (Y90) for Pretreated Isolated Unresectable Colorectal Liver Metastases (IU-CRCLM).
Topics: Antimetabolites, Antineoplastic; Brachytherapy; Colorectal Neoplasms; Combined Modality Therapy; Emb | 2018 |
Implementation and early outcomes for a surgeon-directed hepatic arterial infusion pump program for colorectal liver metastases.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Body Fat Distribution; Colorectal N | 2018 |
Ovarian cancer in BRCA mutation carriers: improved outcome after intraperitoneal (IP) cisplatin.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Carboplatin; Cis | 2014 |
[Doxifluridine, medroxyprogesterone acetate and cyclophosphamide (DMpC) combination therapy is effective against recurrent triple negative breast cancer--a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; Floxurid | 2008 |
Postoperative chemotherapy after neoadjuvant chemoradiation and surgery for rectal cancer: is it essential for patients with ypT0-2N0?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuv | 2009 |
Selective intra-arterial chemotherapy with floxuridine as second- or third-line approach in patients with unresectable colorectal liver metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colorectal Neoplasms; F | 2011 |
Salvage combination chemotherapy with floxuridine, dactinomycin, etoposide, and vincristine (FAEV) for patients with relapsed/chemoresistant gestational trophoblastic neoplasia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Dactinomycin; Dru | 2011 |
Postoperative intraperitoneal 5-fluoro-2'-deoxyuridine added to chemoradiation in patients curatively resected (R0) for locally advanced gastric and gastroesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2012 |
Second-line chemotherapy with paclitaxel and doxifluridine after failure of S-1 in elderly patients with unresectable advanced or recurrent gastric cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; | 2011 |
Early postoperative intraperitoneal chemotherapy following cytoreductive surgery for appendiceal mucinous neoplasms with isolated peritoneal metastasis.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal N | 2012 |
Effectiveness of doxifluridine (5'-DFUR)/docetaxel against advanced/recurrent gastric cancer showing resistance to various anticancer drug regimens.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm | 2002 |
[Evaluation of weekly paclitaxel and doxifluridine (5'-DFUR) combination therapy in patients with advanced or recurrent breast cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dr | 2003 |
[A case of hepatic metastasis and local recurrence from rectal cancer responding to hepatic arterial infusion and systemic chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administrat | 2003 |
Positive response to oral chemoendocrine combination therapy using 5"-deoxy-5-fluorouridine for locally advanced breast cancer with carcinomatous pleurisy: report of a case.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Breast Neoplasms; Drug Therapy, Combination; | 2003 |
[Combination therapy with Anastrozole and 5'-DFUR as a treatment for metastatic breast cancer].
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplas | 2004 |
[A case of long-term survival after chemo-radiation for postoperative local recurrence of rectal cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy | 2004 |
The MMP-9 expression determined the efficacy of postoperative adjuvant chemotherapy using oral fluoropyrimidines in stage II or III colorectal cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemo | 2006 |
[Experience of weekly paclitaxel combined with orally administered doxifluridine therapy for advanced and recurrent gastric cancer-preliminary study].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sche | 2005 |
[A case of chemoradiation with tissue expander for local reccurence of rectal cancer].
Topics: Adenocarcinoma, Mucinous; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antine | 2005 |
[Combined chemotherapy with weekly Paclitaxel and doxifluridine for advanced and recurrent gastric cancers].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; F | 2006 |
The expression of vascular endothelial growth factor determines the efficacy of post-operative adjuvant chemotherapy using oral fluoropyrimidines in stage II or III colorectal cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemo | 2006 |
[A case of local recurrence of rectal cancer in long-term responding to combined therapy of low-dose CPT-11 and 5'-DFUR].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptoth | 2006 |
Doxifluridine combined with weekly paclitaxel for second-line treatment in patients with gastric cancer resistant to TS-1.
Topics: Abdominal Neoplasms; Adrenal Gland Neoplasms; Adult; Aged; Aged, 80 and over; Antineoplastic Combine | 2007 |
[Evaluation of combination therapy of high-dose toremifene and oral chemotherapy].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine | 2007 |
[Combination therapy of high dose doxifluridine (5'-DFUR)+mitomycin C (MMC) for advanced or recurrent colorectal cancer. Joint Research Group in the Osaka Area for Combination Therapy of 5'-DFUR with Other Drugs].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms | 1993 |
[Combined chemotherapy with MMC, ADM, CDDP, etoposide (VP-16) and 5'-DFUR, (MACVD therapy) as a second-line chemotherapy for metastatic gastric cancer: three cases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Etoposide; Female; Floxuridi | 1996 |
[A case of recurrent breast cancer responding to long-term treatment with 5'-DFUR combined with MPA].
Topics: Adenocarcinoma, Scirrhous; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Ad | 1996 |
[Efficacy of combination chemotherapy with mitoxantrone, vincristine, doxifluridine and prednisolone for recurrence of breast cancer].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1997 |
Management of symptomatic locoregional recurrence during regional chemotherapy for colorectal liver metastases.
Topics: Abdominal Neoplasms; Antimetabolites, Antineoplastic; Chemotherapy, Cancer, Regional Perfusion; Colo | 1998 |
[A case of adriamycin and methotrexate-resistant recurrent breast cancer treated with doxifluridine and mitomycin C].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 1999 |
[A case of recurrent breast cancer with carcinoma erysipeloides responding to sequential therapy with docetaxel (TXT) and doxifluridine (5'-DFUR) accompanied by leucovorin (LV)].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2000 |
[Chemotherapy with mitoxantrone for the treatment of recurrent breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Drug Administratio | 2000 |
A case of metastatic breast cancer achieving complete response by combination therapy with 5'-deoxy-5-fluorouridine and cyclophosphamide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Breast Neoplasms; Carcinoma, Duct | 2000 |
[Successful treatment of advanced recurent breast cancer using DMpC therapy as maintenance therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclophospha | 2002 |
[A case of recurrent esophageal cancer maintaining complete long-term response after 5'-DFUR and ftorafur administrations].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Floxurid | 1992 |
[A study of combined chemotherapy with MMC, ADM, CDDP, etoposide (VP-16), 5'DFUR (MAC-VD therapy) in advanced cancer and local relapse of the stomach].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxoru | 1990 |
[Combination therapy with 5'DFUR and MPA as a second line treatment for advanced/recurrent breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Floxuridine; | 1990 |
[Two cases of gastrointestinal cancers with major responses to sequential methotrexate 5-FU plus 5'-DFUR].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Colonic Ne | 1989 |
[A comparative study of 5'-DFUR and tegafur in recurrent breast cancer].
Topics: Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Agents; Breast Neoplasms; Capsules; Diar | 1985 |
Circulating tumor markers and assessment of response to intrahepatic chemotherapy of colon carcinoma.
Topics: Adult; Aged; Antigens, Neoplasm; Antigens, Tumor-Associated, Carbohydrate; Carcinoembryonic Antigen; | 1985 |
Development and characterization of a rat model for locally recurring mammary tumors: sensitivities to 5-fluoro-2'-deoxyuridine, adriamycin, and X-irradiation.
Topics: Animals; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Doxorubicin; Femal | 1988 |
[Clinical trial of 5'-DFUR in patients with recurrent breast cancer].
Topics: Administration, Oral; Adult; Aged; Breast Neoplasms; Drug Administration Schedule; Female; Floxuridi | 1988 |